DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
53	シェーグレン症候群	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04605978 (ClinicalTrials.gov)	December 7, 2020	19/10/2020	Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients	A Phase IIa Efficacy and Safety Trial With Intravenous S95011 in Primary Sjögren's Syndrome Patients: An International, Multicentre, Randomised, Double-blind, Placebo-controlled Study	Primary Sjögren's Syndrome	Drug: S95011 concentrate for solution for infusion;Drug: Placebo concentrate for solution for infusion	Institut de Recherches Internationales Servier	ADIR, a Servier Group company	Not yet recruiting	18 Years	75 Years	All	45	Phase 2	United States;Australia;Canada;France;Germany;Hungary;Spain;United Kingdom

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04605978
(ClinicalTrials.gov)

December 7, 2020

19/10/2020

Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients

A Phase IIa Efficacy and Safety Trial With Intravenous S95011 in Primary Sjögren's Syndrome Patients: An International, Multicentre, Randomised, Double-blind, Placebo-controlled Study

Primary Sjögren's Syndrome

Drug: S95011 concentrate for solution for infusion;Drug: Placebo concentrate for solution for infusion

Institut de Recherches Internationales Servier

ADIR, a Servier Group company

Not yet recruiting

18 Years

75 Years

All

Phase 2

United States;Australia;Canada;France;Germany;Hungary;Spain;United Kingdom